Cardinal Health, Inc. - Q3 2008 (Ended Sept 30, 2007) Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the three-month period ended September 30, 2007 (Q3 of fiscal 2008). Cardinal Health, Inc. operates as a leading provider of healthcare products and services, organized into four reportable segments: Healthcare Supply Chain Services (Pharmaceutical and Medical), Clinical Technologies and Services, and Medical Products and Technologies. The company completed the sale of its Pharmaceutical Technologies and Services (PTS) business in the prior quarter, classifying it as discontinued operations.
Key Financial Metrics
| Metric | Q3 2007 | Q3 2006 |
|---|---|---|
| Revenue | $21,973.4 million | $20,937.5 million |
| Gross Margin | $1,342.2 million (6.1%) | $1,200.5 million (5.7%) |
| Operating Earnings | $489.8 million | $451.2 million |
| Net Earnings | $301.8 million | $270.7 million |
| Diluted EPS | $0.82 | $0.66 |
| Cash from Operating Activities | $408.8 million | $686.7 million |
| Cash and Equivalents (End of Period) | $1,289.6 million | $1,444.2 million |
| Total Debt (Current + Long-term) | $3,734.3 million | Not explicitly stated for 2006 in text |
Note: Total Debt calculated as Current portion of long-term obligations ($386.8M) + Long-term obligations ($3,347.5M).
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 5% ($1.0 billion) driven by pharmaceutical price appreciation (7.0% index), volume growth from existing customers, and acquisitions (notably Viasys Healthcare). This was partially offset by the loss of certain customers ($449 million).
- Profitability: Operating earnings rose 9% to $489.8 million. Gross margin improved by $142 million, aided by acquisitions and price appreciation, though negatively impacted by increased customer discounts ($80 million) in the Pharmaceutical segment.
- Expenses: Selling, General, and Administrative (SG&A) expenses increased 14% ($105 million) primarily due to revenue growth support and acquisition integration costs. Equity-based compensation expense decreased by $11 million year-over-year.
- Cash Flow: Operating cash flow decreased significantly by $278 million to $409 million. This decline was primarily due to a $192 million increase in trade receivables and a $63 million decrease in accounts payable.
- Discontinued Operations: Loss from discontinued operations improved significantly to a $1.4 million loss from a $20.7 million loss in the prior year, as the PTS business was sold and other legacy disposals (HMS, IPD, Humacao) were completed.
Guidance, Outlook, and Risks
- Share Repurchases: The company remains aggressive on capital return, repurchasing approximately $592 million of common shares during the quarter ($342 million under the existing $4.5 billion authorization and $250 million under a new $2.0 billion program announced in August 2007).
- Dividends: Cash dividends declared were $0.12 per share, up from $0.09 in the prior year.
- Special Items: Total special items were $22.5 million, including $14.8 million in restructuring charges (primarily related to the relocation of the Medical segment headquarters) and $5.4 million in acquisition integration charges (primarily Viasys).
- Legal and Regulatory Risks:
- SEC Settlement: The company settled an SEC investigation regarding financial reporting for a $35 million civil penalty (reserved in prior periods) and agreed to retain an independent consultant.
- Shareholder Litigation: A $600 million settlement was reached for federal securities litigation (reserved in Q2 2007), pending final court approval. A $40 million ERISA litigation settlement was approved by the court in October 2007.
- Derivative Actions: A settlement was reached for various derivative actions, with insurance proceeds of $70 million expected to be paid to the company.
- Product Recall: The company is complying with a Consent Decree regarding the Alaris SE pump recall; the product line represents less than 1% of annual revenue.
- Outlook: Management expects competitive pricing pressures to continue but anticipates mitigation through sales growth of higher-margin manufactured products and cost controls. The company believes it has adequate capital resources to fund operations and growth.
Investor Verification Checklist
- Receivables Days Outstanding: Verify the 1.7-day increase in receivable days outstanding and its impact on future working capital needs.
- Customer Loss Impact: Assess the long-term impact of the $449 million revenue loss from customer attrition in the Pharmaceutical segment.
- Legal Settlement Finalization: Confirm the final court approval status of the $600 million securities litigation settlement and the $40 million ERISA settlement.
- Restructuring Progress: Monitor the execution of the $14.8 million restructuring charges, specifically the headquarters relocation and headcount reductions.
- Acquisition Integration: Review the integration progress and cost realization of the Viasys Healthcare acquisition ($88 million cash used in quarter).